210 related articles for article (PubMed ID: 30403163)
1. Renal release of N-acetyl-seryl-aspartyl-lysyl-proline is part of an antifibrotic peptidergic system in the kidney.
Romero CA; Kumar N; Nakagawa P; Worou ME; Liao TD; Peterson EL; Carretero OA
Am J Physiol Renal Physiol; 2019 Jan; 316(1):F195-F203. PubMed ID: 30403163
[TBL] [Abstract][Full Text] [Related]
2. The anti-inflammatory peptide Ac-SDKP is released from thymosin-β4 by renal meprin-α and prolyl oligopeptidase.
Kumar N; Nakagawa P; Janic B; Romero CA; Worou ME; Monu SR; Peterson EL; Shaw J; Valeriote F; Ongeri EM; Niyitegeka JM; Rhaleb NE; Carretero OA
Am J Physiol Renal Physiol; 2016 May; 310(10):F1026-34. PubMed ID: 26962108
[TBL] [Abstract][Full Text] [Related]
3. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP.
Cavasin MA; Rhaleb NE; Yang XP; Carretero OA
Hypertension; 2004 May; 43(5):1140-5. PubMed ID: 15037553
[TBL] [Abstract][Full Text] [Related]
4. Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis.
Zuo Y; Chun B; Potthoff SA; Kazi N; Brolin TJ; Orhan D; Yang HC; Ma LJ; Kon V; Myöhänen T; Rhaleb NE; Carretero OA; Fogo AB
Kidney Int; 2013 Dec; 84(6):1166-75. PubMed ID: 23739235
[TBL] [Abstract][Full Text] [Related]
5. N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice.
Chan GCW; Wu HJ; Chan KW; Yiu WH; Zou A; Huang XR; Lan HY; Lai KN; Tang SCW
Nephrology (Carlton); 2018 Apr; 23(4):297-307. PubMed ID: 28075040
[TBL] [Abstract][Full Text] [Related]
6. The Role of Tβ4-POP-Ac-SDKP Axis in Organ Fibrosis.
Wang W; Jia W; Zhang C
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362069
[TBL] [Abstract][Full Text] [Related]
7. Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?
Kassem KM; Vaid S; Peng H; Sarkar S; Rhaleb NE
Can J Physiol Pharmacol; 2019 Jul; 97(7):589-599. PubMed ID: 30854877
[TBL] [Abstract][Full Text] [Related]
8. The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases.
Kumar N; Yin C
Pharmacol Res; 2018 Aug; 134():268-279. PubMed ID: 29990624
[TBL] [Abstract][Full Text] [Related]
9. Interaction of N-acetyl-seryl-aspartyl-lysyl-proline with the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis attenuates pulmonary fibrosis in silicotic rats.
Gao X; Xu H; Zhang B; Tao T; Liu Y; Xu D; Cai W; Wei Z; Li S; Zhang H; Mao N; Zhang G; Li D; Jin F; Li S; Zhang L; Liu H; Hao X; Yang F
Exp Physiol; 2019 Oct; 104(10):1562-1574. PubMed ID: 31290182
[TBL] [Abstract][Full Text] [Related]
10. Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Castoldi G; di Gioia CR; Bombardi C; Preziuso C; Leopizzi M; Maestroni S; Corradi B; Zerbini G; Stella A
Am J Nephrol; 2013; 37(1):65-73. PubMed ID: 23327833
[TBL] [Abstract][Full Text] [Related]
11. Decreased endogenous levels of Ac-SDKP promote organ fibrosis.
Cavasin MA; Liao TD; Yang XP; Yang JJ; Carretero OA
Hypertension; 2007 Jul; 50(1):130-6. PubMed ID: 17470726
[TBL] [Abstract][Full Text] [Related]
12. Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats.
Peng H; Carretero OA; Raij L; Yang F; Kapke A; Rhaleb NE
Hypertension; 2001 Feb; 37(2 Pt 2):794-800. PubMed ID: 11230375
[TBL] [Abstract][Full Text] [Related]
13. Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.
Myöhänen TT; Tenorio-Laranga J; Jokinen B; Vázquez-Sánchez R; Moreno-Baylach MJ; García-Horsman JA; Männistö PT
Br J Pharmacol; 2011 Aug; 163(8):1666-78. PubMed ID: 21133893
[TBL] [Abstract][Full Text] [Related]
14. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain.
Hrenak J; Paulis L; Simko F
Curr Pharm Des; 2015; 21(35):5135-43. PubMed ID: 26350537
[TBL] [Abstract][Full Text] [Related]
15. Investigating the antifibrotic potential of N-acetyl seryl-aspartyl-lysyl-proline sequence peptides.
Ramasamy V; Ntsekhe M; Sturrock E
Clin Exp Pharmacol Physiol; 2021 Nov; 48(11):1558-1565. PubMed ID: 34347311
[TBL] [Abstract][Full Text] [Related]
16. N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research.
Liao TD; Yang XP; D'Ambrosio M; Zhang Y; Rhaleb NE; Carretero OA
Hypertension; 2010 Feb; 55(2):459-67. PubMed ID: 20026760
[TBL] [Abstract][Full Text] [Related]
17. d-amino acid modification protects N-Acetyl-seryl-aspartyl-lysyl-proline from physiological hydroxylation and increases its antifibrotic effects on hepatic fibrosis.
Zhang X; Zhou J; Zhu Y; He L; Pang Z; Wang Z; Xu C; Zhang C; Hao Q; Li W; Zhang W; Zhang Y; Li M
IUBMB Life; 2019 Sep; 71(9):1302-1312. PubMed ID: 30900390
[TBL] [Abstract][Full Text] [Related]
18. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts.
Rhaleb NE; Peng H; Harding P; Tayeh M; LaPointe MC; Carretero OA
Hypertension; 2001 Mar; 37(3):827-32. PubMed ID: 11244003
[TBL] [Abstract][Full Text] [Related]
19. N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis.
Omata M; Taniguchi H; Koya D; Kanasaki K; Sho R; Kato Y; Kojima R; Haneda M; Inomata N
J Am Soc Nephrol; 2006 Mar; 17(3):674-85. PubMed ID: 16452498
[TBL] [Abstract][Full Text] [Related]
20. Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Castoldi G; di Gioia CR; Bombardi C; Perego C; Perego L; Mancini M; Leopizzi M; Corradi B; Perlini S; Zerbini G; Stella A
Clin Sci (Lond); 2009 Oct; 118(3):211-20. PubMed ID: 20310083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
